File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation

TitlePilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation
Authors
Issue Date2002
PublisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/
Citation
Human Reproduction, 2002, v. 17 n. 7, p. 1738-1740 How to Cite?
AbstractBackground: A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. A new route of administration of misoprostol, the sublingual route, was investigated in this study. Methods: One hundred women who requested legal termination of pregnancy up to 63 days were given 200 mg of oral mifepristone followed 48 h later by 800 μg (4 × 200 μg tablets) of sublingual misoprostol. Results: Ninety-four women (94%) had a complete abortion with this regimen. There was one ongoing pregnancy. The median duration of vaginal bleeding was 15 days. There were no serious complications. However, lower abdominal pain, diarrhoea, chills and fever were the commonest side-effects with incidences of 89, 42, 38 and 79% respectively. Conclusions: The combination of mifepristone and sublingual misoprostol is effective for medical abortion up to 63 days gestation. Randomized trials are required to compare its efficacy and side-effect profile with vaginal misoprostol.
Persistent Identifierhttp://hdl.handle.net/10722/173259
ISSN
2015 Impact Factor: 4.621
2015 SCImago Journal Rankings: 2.271
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTang, OSen_US
dc.contributor.authorXu, Jen_US
dc.contributor.authorCheng, Len_US
dc.contributor.authorLee, SWHen_US
dc.contributor.authorHo, PCen_US
dc.date.accessioned2012-10-30T06:28:51Z-
dc.date.available2012-10-30T06:28:51Z-
dc.date.issued2002en_US
dc.identifier.citationHuman Reproduction, 2002, v. 17 n. 7, p. 1738-1740en_US
dc.identifier.issn0268-1161en_US
dc.identifier.urihttp://hdl.handle.net/10722/173259-
dc.description.abstractBackground: A combination of mifepristone and misoprostol provides an effective method of medical abortion for early pregnancy. A new route of administration of misoprostol, the sublingual route, was investigated in this study. Methods: One hundred women who requested legal termination of pregnancy up to 63 days were given 200 mg of oral mifepristone followed 48 h later by 800 μg (4 × 200 μg tablets) of sublingual misoprostol. Results: Ninety-four women (94%) had a complete abortion with this regimen. There was one ongoing pregnancy. The median duration of vaginal bleeding was 15 days. There were no serious complications. However, lower abdominal pain, diarrhoea, chills and fever were the commonest side-effects with incidences of 89, 42, 38 and 79% respectively. Conclusions: The combination of mifepristone and sublingual misoprostol is effective for medical abortion up to 63 days gestation. Randomized trials are required to compare its efficacy and side-effect profile with vaginal misoprostol.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://humrep.oxfordjournals.org/en_US
dc.relation.ispartofHuman Reproductionen_US
dc.rightsHuman Reproduction. Copyright © Oxford University Press.-
dc.subject.meshAbortifacient Agents, Nonsteroidal - Administration & Dosage - Adverse Effects - Pharmacologyen_US
dc.subject.meshAbortifacient Agents, Steroidal - Administration & Dosage - Adverse Effects - Pharmacologyen_US
dc.subject.meshAbortion, Induced - Methodsen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdministration, Sublingualen_US
dc.subject.meshAdulten_US
dc.subject.meshDrug Synergismen_US
dc.subject.meshFemaleen_US
dc.subject.meshGestational Ageen_US
dc.subject.meshHumansen_US
dc.subject.meshMifepristone - Administration & Dosage - Adverse Effects - Pharmacologyen_US
dc.subject.meshMisoprostol - Administration & Dosage - Adverse Effects - Pharmacologyen_US
dc.subject.meshPilot Projectsen_US
dc.subject.meshPregnancyen_US
dc.subject.meshPregnancy Trimester, Firsten_US
dc.titlePilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestationen_US
dc.typeArticleen_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/humrep/17.7.1738-
dc.identifier.pmid12093832-
dc.identifier.scopuseid_2-s2.0-0036069479en_US
dc.identifier.hkuros82747-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036069479&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume17en_US
dc.identifier.issue7en_US
dc.identifier.spage1738en_US
dc.identifier.epage1740en_US
dc.identifier.isiWOS:000176786000013-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridTang, OS=7006723402en_US
dc.identifier.scopusauthoridXu, J=7407007994en_US
dc.identifier.scopusauthoridCheng, L=34869443100en_US
dc.identifier.scopusauthoridLee, SWH=26030998000en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats